At a recent meeting, the Board of Directors of the American Society for Radiation Oncology (ASTRO) approved a statement regarding the use of proton beam therapy for prostate cancer.
ASTRO is the largest radiation oncology society in the world, with more than 10,000 members who specialize in treating patients with radiation therapies. On March 14, 2013, ASTRO has issued a statement supporting the use of proton beam therapy to treat prostate cancer as long as patients are enrolled in clinical trials or within prospective registries.
ASTRO said that the collection of treatment and outcomes data in these contexts is essential for developing a consensus on the role of proton therapy for prostate cancer. Such information will help radiation oncologists understand the effectiveness of proton therapy compared to other radiation therapy modalities, such as intensity-modulated radiation therapy (IMRT) and brachytherapy.
Noting that proton therapy is not a new treatment for prostate cancer, ASTRO pointed out that its use is still evolving and comparative efficacy evidence is still being developed.
“We look forward to new and innovative research that will more clearly define the role of proton beam therapy for localized prostate cancer among the currently available treatment options”, said ASTRO Chairman Dr. Michael L. Steinberg.